EcoDrugPlus

Histone Deacetylase 6

Ensembl ID : ENSSDUG00000019982
Gene Symbol: HDAC6
2 Cross references
180 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSSDUG00000014235
Gene Symbol: HDAC7
3 Cross references
189 Possible Orthologues:

Histone Deacetylase 7-Like

Ensembl ID : ENSSDUG00000023044
Gene Symbol: LOC111221781
2 Cross references
195 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSSDUG00000014838
Gene Symbol: HDAC8
3 Cross references
205 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSSDUG00000020608
Gene Symbol: HCAR1
2 Cross references
233 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSSDUG00000005445
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSSDUG00000021795
Gene Symbol: HCN4
4 Cross references
212 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSSDUG00000023289
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSSDUG00000001927
Gene Symbol: LOC111222415
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSSDUG00000022942
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSSDUG00000016346
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSSDUG00000002584
Gene Symbol: LOC111224517
4 Cross references
257 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).